CRANE CO (CR)

US2244081046 - Common Stock

135.13  +0.24 (+0.18%)

After market: 135.13 0 (0%)

Fundamental Rating

5

Overall CR gets a fundamental rating of 5 out of 10. We evaluated CR against 133 industry peers in the Machinery industry. CR scores excellent on profitability, but there are some minor concerns on its financial health. CR is valued correctly, but it does not seem to be growing.



7

1. Profitability

1.1 Basic Checks

CR had positive earnings in the past year.
In the past year CR had a positive cash flow from operations.
In the past 5 years CR has always been profitable.
Of the past 5 years CR 4 years had a positive operating cash flow.

1.2 Ratios

CR's Return On Assets of 10.97% is amongst the best of the industry. CR outperforms 84.73% of its industry peers.
CR has a better Return On Equity (18.81%) than 79.39% of its industry peers.
Looking at the Return On Invested Capital, with a value of 10.63%, CR is in the better half of the industry, outperforming 71.76% of the companies in the same industry.
CR had an Average Return On Invested Capital over the past 3 years of 7.98%. This is below the industry average of 10.74%.
The 3 year average ROIC (7.98%) for CR is below the current ROIC(10.63%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 10.97%
ROE 18.81%
ROIC 10.63%
ROA(3y)8.3%
ROA(5y)6.37%
ROE(3y)17%
ROE(5y)14.38%
ROIC(3y)7.98%
ROIC(5y)7.66%

1.3 Margins

CR's Profit Margin of 12.27% is amongst the best of the industry. CR outperforms 81.68% of its industry peers.
In the last couple of years the Profit Margin of CR has grown nicely.
With a decent Operating Margin value of 13.60%, CR is doing good in the industry, outperforming 71.76% of the companies in the same industry.
CR's Operating Margin has been stable in the last couple of years.
With a decent Gross Margin value of 38.58%, CR is doing good in the industry, outperforming 77.10% of the companies in the same industry.
CR's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 13.6%
PM (TTM) 12.27%
GM 38.58%
OM growth 3Y9.04%
OM growth 5Y-0.57%
PM growth 3Y25.78%
PM growth 5Y4.1%
GM growth 3Y4.04%
GM growth 5Y1.65%

6

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so CR is still creating some value.
Compared to 1 year ago, CR has more shares outstanding
Compared to 5 years ago, CR has less shares outstanding
The debt/assets ratio for CR is higher compared to a year ago.

2.2 Solvency

CR has a debt to FCF ratio of 1.34. This is a very positive value and a sign of high solvency as it would only need 1.34 years to pay back of all of its debts.
CR has a better Debt to FCF ratio (1.34) than 85.50% of its industry peers.
CR has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
CR has a Debt to Equity ratio of 0.18. This is in the better half of the industry: CR outperforms 70.23% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF 1.34
Altman-Z N/A
ROIC/WACC1.21
WACC8.8%

2.3 Liquidity

CR has a Current Ratio of 2.34. This indicates that CR is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.34, CR is in the better half of the industry, outperforming 60.31% of the companies in the same industry.
CR has a Quick Ratio of 1.58. This is a normal value and indicates that CR is financially healthy and should not expect problems in meeting its short term obligations.
CR's Quick ratio of 1.58 is fine compared to the rest of the industry. CR outperforms 69.47% of its industry peers.
Industry RankSector Rank
Current Ratio 2.34
Quick Ratio 1.58

3

3. Growth

3.1 Past

The earnings per share for CR have decreased strongly by -44.42% in the last year.
The Earnings Per Share has been decreasing by -4.15% on average over the past years.
Looking at the last year, CR shows a very negative growth in Revenue. The Revenue has decreased by -43.62% in the last year.
The Revenue has been decreasing by -9.01% on average over the past years.
EPS 1Y (TTM)-44.42%
EPS 3Y13.05%
EPS 5Y-4.15%
EPS growth Q2Q-57.75%
Revenue 1Y (TTM)-43.62%
Revenue growth 3Y-10.77%
Revenue growth 5Y-9.01%
Revenue growth Q2Q9.67%

3.2 Future

CR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.07% yearly.
The Revenue is expected to grow by 6.29% on average over the next years.
EPS Next Y110.02%
EPS Next 2Y51.95%
EPS Next 3Y13.06%
EPS Next 5Y12.07%
Revenue Next Year75.37%
Revenue Next 2Y35.8%
Revenue Next 3Y6.57%
Revenue Next 5Y6.29%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 31.57, the valuation of CR can be described as expensive.
Based on the Price/Earnings ratio, CR is valued a bit more expensive than the industry average as 61.07% of the companies are valued more cheaply.
When comparing the Price/Earnings ratio of CR to the average of the S&P500 Index (26.48), we can say CR is valued inline with the index average.
CR is valuated correctly with a Price/Forward Earnings ratio of 14.88.
Based on the Price/Forward Earnings ratio, CR is valued a bit cheaper than 78.63% of the companies in the same industry.
CR is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 22.79, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 31.57
Fwd PE 14.88

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, CR is valued a bit more expensive than the industry average as 67.94% of the companies are valued more cheaply.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CR is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 41.59
EV/EBITDA 23.58

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CR has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as CR's earnings are expected to grow with 13.06% in the coming years.
PEG (NY)0.29
PEG (5Y)N/A
EPS Next 2Y51.95%
EPS Next 3Y13.06%

2

5. Dividend

5.1 Amount

CR has a yearly dividend return of 0.61%, which is pretty low.
CR's Dividend Yield is comparable with the industry average which is at 1.64.
With a Dividend Yield of 0.61, CR pays less dividend than the S&P500 average, which is at 2.34.
Industry RankSector Rank
Dividend Yield 0.61%

5.2 History

CR has paid a dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

248.30% of the earnings are spent on dividend by CR. This is not a sustainable payout ratio.
DP248.3%
EPS Next 2Y51.95%
EPS Next 3Y13.06%

CRANE CO

NYSE:CR (3/28/2024, 8:04:00 PM)

After market: 135.13 0 (0%)

135.13

+0.24 (+0.18%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap7.71B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield 0.61%
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 31.57
Fwd PE 14.88
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.29
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 10.97%
ROE 18.81%
ROCE
ROIC
ROICexc
ROICexgc
OM 13.6%
PM (TTM) 12.27%
GM 38.58%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.89
Health
Industry RankSector Rank
Debt/Equity 0.18
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.34
Quick Ratio 1.58
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-44.42%
EPS 3Y13.05%
EPS 5Y
EPS growth Q2Q
EPS Next Y110.02%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-43.62%
Revenue growth 3Y-10.77%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y